It's good to see some of the information we've not
Post# of 15624
(Total Views: 569)
Posted On: 04/16/2019 7:12:47 PM
It's good to see some of the information we've not seen before, but frankly nothing I've seen would change my mind about ever reducing the shares outstanding to potentially a few millions or less, with half a billion still authorized.
I'm sorry the company simply came out and said no meeting when they could have discussed the future in much greater depth for the same P.R. price, but that's been my criticism of the company all along, they don't want to give investors reasons to invest.
If the company can get patent approval, then they'll have something to build on. Without such approval, I cannot see a BP or other major investor pouring in the kind of money needed to take clinical trials to their conclusions. It may be possible to demonstrate efficacy in a small Phase 2 trial, then put the product on the market, but if there is no hope of patent approval, sales will be limited as look alike products will be developed. At least the company would have some revenue, but they need to own intellectual property before they can be considered a biotech rather than just another cannabis based producer.
If we substituted Corn for Cannabis, I love the corn that can be purchased in practically every market, for the most part it's a sweet and tasty after days as corn used to be decades ago when you bought it fresh in the field. My point is that you can now get it anywhere. Our products can only be tremendous successes if they're exclusive, if others can copy them they'll be just like the corn that can be purchased anywhere.
Gary
I'm sorry the company simply came out and said no meeting when they could have discussed the future in much greater depth for the same P.R. price, but that's been my criticism of the company all along, they don't want to give investors reasons to invest.
If the company can get patent approval, then they'll have something to build on. Without such approval, I cannot see a BP or other major investor pouring in the kind of money needed to take clinical trials to their conclusions. It may be possible to demonstrate efficacy in a small Phase 2 trial, then put the product on the market, but if there is no hope of patent approval, sales will be limited as look alike products will be developed. At least the company would have some revenue, but they need to own intellectual property before they can be considered a biotech rather than just another cannabis based producer.
If we substituted Corn for Cannabis, I love the corn that can be purchased in practically every market, for the most part it's a sweet and tasty after days as corn used to be decades ago when you bought it fresh in the field. My point is that you can now get it anywhere. Our products can only be tremendous successes if they're exclusive, if others can copy them they'll be just like the corn that can be purchased anywhere.
Gary
(1)
(0)